Long Non-Coding TP73-AS1: A Potential Biomarker and Therapeutic Target in Cancer

Area of Science:

• * Molecular oncology
• * Cancer genomics
• * RNA biology

Background:

• * Tumor protein 73 antisense RNA 1 (TP73-AS1) is a long non-coding RNA (lncRNA) with dysregulated expression in various cancers.
• * Aberrant TP73-AS1 expression correlates with cancer occurrence, drug resistance, and patient prognosis.
• * Understanding TP73-AS1's regulatory roles offers new avenues for cancer diagnosis and treatment.

Purpose of the Study:

• * To review the molecular structure and dual regulatory functions of TP73-AS1 in cancer.
• * To elucidate the molecular mechanisms through which TP73-AS1 influences cancer progression.
• * To highlight the clinical significance and therapeutic potential of TP73-AS1 in oncology.

Main Methods:

• * Literature review of existing studies on TP73-AS1 in cancer.
• * Analysis of TP73-AS1's molecular interactions, including protein binding and signaling pathway regulation.
• * Examination of TP73-AS1's role as a molecular sponge for microRNAs.
• * Compilation of data on TP73-AS1's involvement in specific cancers like gastric, lung, and colorectal cancer.

Main Results:

• * TP73-AS1 exhibits diverse molecular mechanisms in cancer, including protein binding, signaling pathway modulation, and acting as a molecular sponge.
• * TP73-AS1 plays a significant role in the pathogenesis of common malignancies such as gastric cancer (GC), lung cancer, and colorectal cancer (CRC).
• * Single nucleotide polymorphisms (SNPs) in TP73-AS1 are associated with increased risk for GC and CRC.

Conclusions:

• * TP73-AS1 is a crucial player in cancer development and progression through multiple molecular pathways.
• * TP73-AS1 demonstrates significant potential as a diagnostic biomarker and a therapeutic target for various cancers.
• * Further research into TP73-AS1's functions could lead to novel clinical strategies for cancer management.